Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Axial Biotherapeutics is raising $8,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Donabedian played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. Axial Biotherapeutics, leader of a paradigm shift in treating CNS disorders, has taken a radical departure from conventional neuroscience with its approach that treats disease through the gut-brain axis. In recent years, studies suggest a significant impact of the gut microbiome in human health and disease. Axial’s focus is to develop gut-selective, best-in-class therapies to treat CNS-based disorders by targeting the GI.

To learn more about Axial Biotherapeutics, visit http://www.axialbiotherapeutics.com/

Contact:
David Donabedian, Chief Executive Officer
781-701-8468
david@axialbiotherapeutics.com
https://www.linkedin.com/in/david-h-donabedian-73050a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved